Jacqueline H. Lee

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 331 citations

Medicine, Cardiology, Pharmacology +14

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali et al. · The Lancet · 2011 · 261 citations

Medicine, Cardiology, Pharmacology +11

Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina

Barry Greenberg, Willis Chou, Khalil G. Saikali et al. · JACC Heart Failure · 2014 · 65 citations · Full text

Medicine, Cardiology, Pharmacology +17

A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosis

Jeremy M. Shefner, Merit Cudkowicz, Orla Hardiman et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2019 · 46 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

The Selective Cardiac Myosin Activator, CK-1827452, Increases Left Ventricular Systolic Function by Increasing Ejection Time: Results of a First-in-Human Study of a Unique and Novel Mechanism

John R. Teerlink, Fady I. Malik, Cyril P. Clarke et al. · Journal of Cardiac Failure · 2006 · 14 citations

Life Sciences, Cardiology, Physiology +13